Nanoviricides, Inc. 8-K Filing
Ticker: NNVC · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1379006
| Field | Detail |
|---|---|
| Company | Nanoviricides, Inc. (NNVC) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Nanoviricides, Inc. (ticker: NNVC) to the SEC on Nov 26, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (egistered : Common Stock, par value $0.00001 per share NNVC NYSE -American Ite).
How long is this filing?
Nanoviricides, Inc.'s 8-K filing is 2 pages with approximately 658 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 658 words · 3 min read · ~2 pages · Grade level 14.5 · Accepted 2025-11-26 16:30:33
Key Financial Figures
- $0.00001 — egistered : Common Stock, par value $0.00001 per share NNVC NYSE -American Ite
Filing Documents
- tm2531747d1_8k.htm (8-K) — 31KB
- 0001104659-25-116457.txt ( ) — 191KB
- nnvc-20251122.xsd (EX-101.SCH) — 3KB
- nnvc-20251122_lab.xml (EX-101.LAB) — 33KB
- nnvc-20251122_pre.xml (EX-101.PRE) — 22KB
- tm2531747d1_8k_htm.xml (XML) — 3KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On November 22, 2025, NanoViricides, Inc. (the "Company") reconvened and held its 2025 Annual Meeting of Stockholders (the "Meeting") . At the meeting, 7,906,820 shares of the Company's common stock and 838,025 shares of Series A Convertible Preferred Stock ("Series A Preferred Shares") entitled to vote at the Meeting, as of the record date of October 3, 2025, were present in person or by proxy, representing approximately 61% of the Company's outstanding voting capital stock and constituting a quorum for the transaction of business. With a quorum present, the required shareholders approved the following proposals: (i) the re-election of Anil Diwan as a Class I Director for a two-year term expiring at the 2027 annual meeting of stockholders and until their successor is duly elected and qualified or until their earlier resignation or removal; (ii) to conduct an advisory vote on the compensation of the Company's named Executive Officers; and (iii) the ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026. Each proposal is described in more detail in the Company's Proxy Statement filed with the Securities and Exchange Commission on October 7, 2025. The voting results of the shares of the Company's voting stock for each proposal are set forth below: Proposal 1 – Election of Director - Re-Election of Anil Diwan as a Class I Director: Director For Against Votes Abstained Anil Diwan 9,757,652 173,096 48,971 Proposal 2 – Advisory Vote on Executive Compensation – To conduct an advisory vote on the compensation of the Company's named Executive Officers: Votes For Votes Against Votes Abstained 9,500,223 420,374 59,122 Proposal 3 – Ratification of Accounting Firm – To ratify the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fis
SIGNATURES
SIGNATURES PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED. NANOVIRICIDES, INC. Date: November 26, 2025 By: /s/ Anil Diwan Name: Anil Diwan Title: Chairman, President